2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振， 百济神州涨超3%，石药集团、中国生物制药、三生制药集体跟涨。 100%创新药研发标的——港股通创新药ETF（520880）高开后上探2.75%，收涨1.77%成功连阳，一并 站上10日均线，全天成交3.81亿元。 2月8日晚，信达生物公告，公司与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研 发进程。信达将获3.5亿美元首付款，最高可获85亿美元里程碑付款及大中华区以外净销售额梯度分 成。 2025年中国创新药License-out总交易规模达到创纪录的1357亿美元，2026年开年以来重磅合作频出，除 信达外，1月份石药-阿斯利康（185亿美元）、荣昌-艾伯维（56亿美元）两笔超级BD均充分验证国产 创新药管线的全球价值。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大 ...

Core Viewpoint - The competition for GLP-1 weight loss drugs in China by 2026 will shift from who can get approved first to who can survive under pressure from payment and distribution channels while continuing to grow [4] Group 1: Market Dynamics - In 2025, the market will see a competitive landscape where Novo Nordisk's semaglutide system dominates, Eli Lilly's tirzepatide penetrates the market, and domestic players like Innovent and Yinoo differentiate themselves with dual-target GLP-1/GCG and long-acting GLP-1 products [6] - By 2026, the market will face intensified competition as insurance pricing pressures increase, major players normalize price wars, and the patent for semaglutide approaches expiration, leading to a surge in supply from biosimilars and similar products [6][9] Group 2: Company Strategies - For Novo Nordisk, the key challenge in 2025 is not new drug approvals but the rare decline in core products in Greater China, necessitating aggressive pricing and channel policies to maintain market share [7] - Eli Lilly's strategy involves a dual approach: using insurance pricing to gain scale in hospitals while adopting flexible retail strategies to capture weight management users [7] - Domestic companies face a common challenge of needing to reassess revenue models as major players drive prices down and insurance anchors lower, making it difficult to sustain high pricing and growth expectations [9] Group 3: New Variables in 2026 - The introduction of oral small-molecule GLP-1s will significantly increase competition in outpatient settings, with Eli Lilly's Orforglipron expected to enhance long-term adherence and channel integration [10] - The impact of insurance and hospital procurement will be felt in 2026, with products entering insurance quickly expanding prescription volumes but requiring acceptance of lower payment prices [10] - The market will see a surge of new domestic players, including those with recently approved products and innovative candidates that could disrupt the market structure [11][12] Group 4: Price Structure and Market Segmentation - By late 2026, the GLP-1 market in China will likely form a three-tier structure: a premium tier for original and strong innovative brands, a second tier for domestic innovations, and a third tier for biosimilars and similar products competing on price [20] - The expiration of semaglutide's patent will lead to a significant shift in the pricing landscape, requiring companies to adopt more conservative revenue expectations and refined commercialization strategies to avoid price wars [21]

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

Core Viewpoint - After several days of adjustments, Hong Kong's tech assets have seen a significant rebound, with sectors such as the internet and innovative pharmaceuticals rising together, particularly highlighted by a more than 30% surge in the large model company Zhiyu [1] Group 1: Market Performance - The Hong Kong Stock Connect Technology ETF (159101.SZ) saw its market price increase by nearly 2% during intraday trading, with holdings like Alibaba, Tencent, SMIC, BYD, Hua Hong, BeiGene, and Xpeng all rising over 2% [1] - The PE-TTM of the Hong Kong Stock Connect Technology ETF is at 21 times, which is significantly lower than other major tech indices such as NASDAQ, ChiNext, and STAR Market, positioned at the 30th percentile of the last 10 years [1] Group 2: Sector Coverage - The index of the Hong Kong Stock Connect Technology ETF has filled the gap in innovative pharmaceuticals while also covering leading companies in internet platforms, smart driving, and innovative drugs, including Alibaba, Tencent, BYD, BeiGene, and WuXi Biologics, all of which are eligible for Hong Kong Stock Connect [1] - The ETF is not subject to QDII foreign exchange quota restrictions, providing better liquidity for investors [1] Group 3: Trading Features - The Hong Kong Stock Connect Technology ETF is listed on the Shenzhen Stock Exchange and supports T+0 intraday flexible trading, offering A-share investors a low-threshold option without the need for cross-border accounts or currency exchange [1]

2月9日，港股科技板块高开，华虹半导体涨超4%，中芯国际、百济神州涨超2%，阿里巴巴-W涨 1.81%，港股通科技ETF招商（159125）涨1.15%。 港股上周伴随全球风险资产波动，恒生科技指数回落至5400点下方，但资金整体呈"逆势"流入，据统 计，南向资金、港股科技类ETF基金一周合计净流入超670亿元。 从过往经验来看，港股通科技指数长期表现更优。自2017年初以来至2026年2月6日，港股通科技指数累 涨153.72%，同期港股通互联网指数、恒生科技指数涨0.99%、45.74%。 | 康昌 证券代码 | 证券简称 | 区间涨跌幅 | | | --- | --- | --- | --- | | | | [区间首日] 2017-01-01 [区间尾日] 最新收盘日 | | | | | [单位] % | | | 1 987008.CNI 港股通科技 | | | 153.72 | | 2 931637.CSI | 港股通互联网 | | 0.99 | | 3 HSTECH.HI | 恒生科技 | | 45.74 | 数据来源：Wind，截至2026.2.6 ETF方面，上周挂钩港股科技类指数的ETF产品整 ...

Core Viewpoint - The Hang Seng Technology Index has experienced over 80 trading days of adjustment since October last year, with a drawdown nearing 20%, exceeding historical averages [1] Group 1: Market Performance - The adjustment duration and magnitude have surpassed historical averages, which are 20 trading days and an 18% drawdown respectively [1] - The Hong Kong technology sector is noted for its resilience, while the A-share technology sector is recognized for its greater elasticity [1] Group 2: Investment Outlook - Huaxia Fund is optimistic about the rebound potential of Hong Kong technology stocks, highlighting the sector's core assets in AI, including computing power, models, software applications, and hardware terminals [1] - The integration of AI with e-commerce, entertainment, and enterprise services is expected to generate significant products [1] Group 3: Investment Products - Investors are encouraged to consider Hong Kong technology-related ETFs, such as the Hang Seng Technology Index ETF (513180.SH), Hang Seng Internet ETF (513330.SH), and Hong Kong Stock Connect Technology ETF (159101.SZ), all of which are listed on mainland exchanges and support T+0 trading [1] - The Hang Seng Internet ETF (513330.SH) focuses on major Hong Kong internet companies like Alibaba, Baidu, Tencent, NetEase, and JD.com [1] - The Hong Kong Stock Connect Technology ETF (159101.SZ) covers internet and new energy vehicles while also including leading innovative pharmaceutical companies like BeiGene, WuXi Biologics, and Innovent Biologics [1]

Group 1 - The renewable energy sector is active, with the solar photovoltaic concept leading the gains, as Tesla evaluates multiple sites in the U.S. to expand its solar cell manufacturing business, aiming for an annual production capacity of 100 gigawatts over the next three years [1] - SpaceX founder Elon Musk has proposed a strategic plan to deploy 100 gigawatts of solar AI satellite energy networks in space annually, indicating that space photovoltaic technology can drive and operate artificial intelligence at a low cost [1] - In China, the "14th Five-Year Plan" suggests that the sixth-generation mobile communication will become a new economic growth point, with a focus on integrating ground and satellite networks, which is expected to boost satellite launches and the space photovoltaic industry [1] Group 2 - As of February 9, 2026, the STAR Market 100 Index (000698) has seen significant gains, with component stocks such as Shijia Photon rising by 9.31% and Rongbai Technology by 8.15% [2] - The STAR Market 100 Index is composed of 100 securities selected from the STAR Market based on market capitalization and liquidity, reflecting the overall performance of different market capitalization companies [2] - The top ten weighted stocks in the STAR Market 100 Index as of January 30, 2026, include Huahong Semiconductor and Yuanjie Technology, accounting for a total of 27.42% of the index [2]

Core Viewpoint - The Hang Seng Technology Index has experienced a decline due to tax concerns and the impact of the AI "red envelope war" on profitability, falling below the 250-day moving average, which has historically served as a support line during major market rallies [1] Group 1: Market Performance - The Hang Seng Technology Index has dropped below the 250-day moving average, a critical support level that has not been significantly breached during previous major market rallies, including those in 2016-2017 and 2020-2021 [1] - After several days of trading below the 250-day moving average, the Hang Seng Technology Index has begun to rebound, indicating that the short-term downward momentum has been sufficiently released [1] Group 2: Fund Flows - Recent large net subscriptions have been observed in technology-related ETFs such as the Hang Seng Technology Index ETF (513180.SH), Hang Seng Internet ETF (513330.SH), and the Hong Kong Stock Connect Technology ETF (159101.SZ), suggesting that funds may be optimistic about the current valuation [1] - The Hang Seng Internet ETF (513330.SH) focuses on major Hong Kong internet giants including Alibaba, Baidu Group, Tencent Holdings, and NetEase, while the Hong Kong Stock Connect Technology ETF (159101.SZ) includes leading innovative pharmaceutical companies like BeiGene, WuXi Biologics, and Innovent Biologics [1]

Group 1 - The Hong Kong stock market showed a strong opening on February 9, with the Hang Seng Index rising by 1.59%, the State-owned Enterprises Index increasing by 1.54%, and the Technology Index up by 1.9% [1] - The Hang Seng Biotechnology Index, focusing on innovative drugs, performed robustly, with the largest ETF tracking this index (159892) rising nearly 2% [1] - The innovative drug sector is expected to enter a profit realization acceleration phase by 2025, with companies like Innovent Biologics and Rongchang Biopharmaceuticals turning losses into profits, while companies like 3SBio are significantly increasing their performance [1] Group 2 - The strong performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core product volume growth supported by medical insurance becoming the foundation for performance growth [1] - External collaborations, such as business development (BD) partnerships, are becoming important drivers for enhancing performance in the innovative drug sector [1] - The Hang Seng Medical ETF (159892) focuses on innovative drugs, CXO, and related industries, benefiting from the advantages of the Hong Kong Stock Exchange's 18A system, covering numerous innovative targets like BeiGene and Innovent Biologics, and is expected to continue its valuation recovery trend under catalysts like overseas expansion of innovative drugs and commercial insurance directories [1]

Core Viewpoint - The Hong Kong stock market for innovative drugs is experiencing significant growth, with the Hong Kong Stock Connect Innovative Drug ETF (159570) rising nearly 2% and achieving a trading volume exceeding 750 million yuan, indicating renewed investor interest [1][3]. Group 1: Company Developments - Innovent Biologics announced a strategic partnership with Eli Lilly to advance global R&D in oncology and immunology, receiving an upfront payment of $350 million and potential milestone payments totaling up to $8.5 billion [3]. - The stock performance of key companies within the ETF is positive, with Innovent Biologics up over 4%, BeiGene and China National Pharmaceutical Group up over 3%, and CSPC Pharmaceutical Group and Hansoh Pharmaceutical up over 1% [3][4]. Group 2: Industry Trends - The Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," with a projected increase in License-out transactions from $2.562 billion in 2017 to $140.274 billion by 2025, indicating a significant leap in global recognition [5]. - By 2025, over 70% of companies in the innovative drug sector are expected to achieve revenue growth, with companies like BeiGene reporting revenues exceeding 36 billion yuan, showcasing strong commercialization capabilities [6]. - The innovative drug sector is entering a phase of profitability, with companies like Innovent Biologics and Rongchang Biologics achieving breakeven, while others like Elysium and Rongchang Biologics maintain robust growth [9][11]. Group 3: Investment Opportunities - The innovative drug sector is expected to see a surge in clinical data releases in 2026, with major academic conferences likely to provide further validation for domestic innovative drugs [8]. - Investment strategies should focus on core areas such as small nucleic acids, bispecific antibodies, and ADCs, while also capitalizing on performance forecast windows to identify high-potential stocks [8][12].